March 1, 2021 -- SalioGen Therapeutics has closed $20 million in financing to advance its exact DNA integration technology (EDIT) platform for nonviral gene therapy.
Proceeds will be used to support preclinical validation of the EDIT platform for the development of durable, safe, and affordable in vivo gene therapies.
EDIT is used to simultaneously deliver an RNA sequence that encodes saliogase, a mammalian-derived enzyme, with a DNA sequence of any length to cells of interest via lipid nanoparticles. Transiently expressed saliogase integrates the supplied DNA into a precise, defined location in the recipient genome without the need for homologous recombination.
The company will initially focus on the development of its lead programs in familial hypercholesterolemia and inherited macular degeneration.
The series A financing round was led by PBM Capital. In conjunction with the financing, SalioGen has strengthened its board of directors and its scientific advisory board.
Copyright © 2021 scienceboard.net